
PASSAGE BIO (PASG) Stock Forecast & Price Target
PASSAGE BIO (PASG) Analyst Ratings
Bulls say
Passage Bio Inc. is positioned positively due to its focus on innovative one-time gene therapies aimed at neurodegenerative diseases, with the development of PBFT02 which may benefit from an amended trial protocol allowing for earlier intervention. The potential for accelerated regulatory approval based on biomarker endpoints could significantly shorten trial timelines and enhance the program's value proposition, provided that biomarker and clinical data show comparable results with competing therapies. Additionally, the company's operational strategy to enroll patients in Cohort 3 in parallel could expedite overall trial progress, potentially leading to a more favorable market positioning.
Bears say
Passage Bio Inc. faces significant risks that contribute to a negative outlook on its stock, particularly regarding the development of its gene therapy programs, which are still in early stages. Delays in clinical timelines, along with potential safety concerns and challenges in manufacturing capacity, could adversely affect market sentiment and lead to downward revisions of financial estimates. Additionally, the complex nature of AAV-based gene therapies increases the likelihood of unforeseen setbacks, further complicating the pathway to regulatory alignment and product commercialization.
This aggregate rating is based on analysts' research of PASSAGE BIO and is not a guaranteed prediction by Public.com or investment advice.
PASSAGE BIO (PASG) Analyst Forecast & Price Prediction
Start investing in PASSAGE BIO (PASG)
Order type
Buy in
Order amount
Est. shares
0 shares